Vivos Inc (RDGL)

[Grig81]

$RDGL Guys— KNOW WHAT YOU OWN. This is an amazing time for Vivos right now. It’s hard to believe anyone would sell at this time, given the key catalyst for RDGL— the anticipated Investigational Device Exemption (IDE) submission to the FDA will occur by the end of Q2. This green light would allow Vivos to begin human trials for their Radiogel therapy, a potential game-changer in cancer treatment.

Successful human trials will -00% propel RDGL to new heights. Investors are hungry for positive FDA results, and with them will come a surge in stock price. Selling before these trials even begin means missing out on significant gains.

Beyond the IDE

Also— Vivos isn't a one-trick pony. They already boast:

FDA Breakthrough Device Designation for Radiogel, highlighting its potential.
Commercially Available IsoPet for Animals: Providing revenue and demonstrating the technology's viability.
Expanding IsoPet Network: Three new certified clinics for wider animal treatment reach.
The Takeaway

Q2 is shaping up to be a pivotal time for RDGL. With the FDA IDE submission looming, there's a strong chance of positive developments that could send the stock price soaring